The Apex Times
Above the Noise
Business Wire
BusinessNvidia and MediaTek Expand Partnership as Jensen Huang Flags Bigger CollaborationThe Apex TimesBusinessDeere sees analyst upgrade as Lumentum gets fresh coverage in Wall Street top callsThe Apex TimesBusinessSalesforce tells investors Agentforce AI is driving a sharp jump in subscription revenueThe Apex TimesBusinessNvidia CEO Jensen Huang tells investors the “AI factory” push and sovereign cloud buildout are central to future growthThe Apex TimesBusinessCostco and Target face a familiar test, shoppers and investors decide which discount model is improving fasterThe Apex TimesBusinessTim Cook’s final day at Apple puts focus on John Ternus’s first steps as CEOThe Apex TimesBusinessPrime momentum could reinforce Amazon’s retail and ad engine, market observers argueThe Apex TimesBusinessNvidia to invest $3.5 billion in MediaTek via convertible bonds as AI chip alliance broadensThe Apex TimesBusinessCaterpillar’s ‘ABR Buy’ call highlights how analyst ratings still shape stock chatterThe Apex TimesBusinessAmazon shares draw focus as AWS growth accelerates and advertising plus AI gain market attentionThe Apex TimesBusinessAT&T Margin Expansion Attracts Attention, but Sustainability Depends on Mix, Costs and PricingThe Apex TimesBusinessNetflix says filming has begun on a new series from the creators of KleoThe Apex TimesBusinessNvidia and MediaTek Expand Partnership as Jensen Huang Flags Bigger CollaborationThe Apex TimesBusinessDeere sees analyst upgrade as Lumentum gets fresh coverage in Wall Street top callsThe Apex TimesBusinessSalesforce tells investors Agentforce AI is driving a sharp jump in subscription revenueThe Apex TimesBusinessNvidia CEO Jensen Huang tells investors the “AI factory” push and sovereign cloud buildout are central to future growthThe Apex TimesBusinessCostco and Target face a familiar test, shoppers and investors decide which discount model is improving fasterThe Apex TimesBusinessTim Cook’s final day at Apple puts focus on John Ternus’s first steps as CEOThe Apex TimesBusinessPrime momentum could reinforce Amazon’s retail and ad engine, market observers argueThe Apex TimesBusinessNvidia to invest $3.5 billion in MediaTek via convertible bonds as AI chip alliance broadensThe Apex TimesBusinessCaterpillar’s ‘ABR Buy’ call highlights how analyst ratings still shape stock chatterThe Apex TimesBusinessAmazon shares draw focus as AWS growth accelerates and advertising plus AI gain market attentionThe Apex TimesBusinessAT&T Margin Expansion Attracts Attention, but Sustainability Depends on Mix, Costs and PricingThe Apex TimesBusinessNetflix says filming has begun on a new series from the creators of KleoThe Apex TimesBusinessNvidia and MediaTek Expand Partnership as Jensen Huang Flags Bigger CollaborationThe Apex TimesBusinessDeere sees analyst upgrade as Lumentum gets fresh coverage in Wall Street top callsThe Apex TimesBusinessSalesforce tells investors Agentforce AI is driving a sharp jump in subscription revenueThe Apex TimesBusinessNvidia CEO Jensen Huang tells investors the “AI factory” push and sovereign cloud buildout are central to future growthThe Apex TimesBusinessCostco and Target face a familiar test, shoppers and investors decide which discount model is improving fasterThe Apex TimesBusinessTim Cook’s final day at Apple puts focus on John Ternus’s first steps as CEOThe Apex TimesBusinessPrime momentum could reinforce Amazon’s retail and ad engine, market observers argueThe Apex TimesBusinessNvidia to invest $3.5 billion in MediaTek via convertible bonds as AI chip alliance broadensThe Apex TimesBusinessCaterpillar’s ‘ABR Buy’ call highlights how analyst ratings still shape stock chatterThe Apex TimesBusinessAmazon shares draw focus as AWS growth accelerates and advertising plus AI gain market attentionThe Apex TimesBusinessAT&T Margin Expansion Attracts Attention, but Sustainability Depends on Mix, Costs and PricingThe Apex TimesBusinessNetflix says filming has begun on a new series from the creators of KleoThe Apex TimesBusinessNvidia and MediaTek Expand Partnership as Jensen Huang Flags Bigger CollaborationThe Apex TimesBusinessDeere sees analyst upgrade as Lumentum gets fresh coverage in Wall Street top callsThe Apex TimesBusinessSalesforce tells investors Agentforce AI is driving a sharp jump in subscription revenueThe Apex TimesBusinessNvidia CEO Jensen Huang tells investors the “AI factory” push and sovereign cloud buildout are central to future growthThe Apex TimesBusinessCostco and Target face a familiar test, shoppers and investors decide which discount model is improving fasterThe Apex TimesBusinessTim Cook’s final day at Apple puts focus on John Ternus’s first steps as CEOThe Apex TimesBusinessPrime momentum could reinforce Amazon’s retail and ad engine, market observers argueThe Apex TimesBusinessNvidia to invest $3.5 billion in MediaTek via convertible bonds as AI chip alliance broadensThe Apex TimesBusinessCaterpillar’s ‘ABR Buy’ call highlights how analyst ratings still shape stock chatterThe Apex TimesBusinessAmazon shares draw focus as AWS growth accelerates and advertising plus AI gain market attentionThe Apex TimesBusinessAT&T Margin Expansion Attracts Attention, but Sustainability Depends on Mix, Costs and PricingThe Apex TimesBusinessNetflix says filming has begun on a new series from the creators of KleoThe Apex Times
Back to front
Eli Lilly to buy Merida Biosciences in deal valued at up to $2.875 billion
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 31, 8:06 AM EDT

Eli Lilly to buy Merida Biosciences in deal valued at up to $2.875 billion

The acquisition is aimed at expanding Eli Lilly’s antibody pipeline, including programs tied to Graves’ disease, thyroid eye disease and food allergy.

2 min readEditor-approved Apex article

Eli Lilly is preparing to acquire Merida Biosciences for up to $2.875 billion, adding a set of antibody-based assets focused on autoimmune and immune-mediated conditions, according to a market report published Wednesday.

The transaction is framed around Merida’s pipeline of antibodies targeting biological pathways involved in Graves’ disease and thyroid eye disease, as well as conditions that include food allergy. The report describes the deal as a way for Lilly to build out its antibody portfolio in areas where demand for more targeted therapies has been rising.

Because the report characterizes the pipeline by disease target rather than by trial stage, it does not provide enough detail to determine how advanced any specific program is, such as whether assets are in preclinical research, early human testing, or later-stage studies.

Lilly’s interest in antibodies aligns with a broader industry strategy that uses monoclonal antibodies, which are lab-made proteins designed to bind specific targets in the body, to modulate immune activity. For companies, this can be attractive because antibody medicines can be engineered for selectivity and may translate into clearer mechanisms of action than broader immunosuppressants.

The deal also reflects ongoing pharmaceutical consolidation in specialty areas, particularly in immune and inflammatory diseases. As larger drugmakers expand beyond traditional small molecules, acquisitions can accelerate entry into new mechanisms without waiting for internal discovery timelines to mature.

Still, key deal terms and program specifics were not laid out in the market report. In particular, it does not describe the breakdown of the up-to-amount consideration, such as how much is upfront versus contingent on milestones, nor does it provide trial names, patient endpoints, or regulatory timing for each antibody candidate.

Investors and patients will likely look next for additional disclosure on the asset-by-asset pipeline, including the maturity of each program and whether any are partnered or licensed. Lilly may also clarify how Merida’s programs fit into its existing antibody platform and what, if any, near-term development steps are expected after the close.

Why It Matters

  • The deal expands Lilly’s antibody strategy in autoimmune and immune-mediated disease categories, which may broaden the company’s long-term growth options.
  • Buying instead of building can shorten time to a new mechanism of action, especially in competitive immunology markets.
  • If Merida’s assets reach clinical or regulatory milestones, the contingent components of the deal could change the overall economics for Lilly.
  • The market will likely focus on how advanced the acquired programs are and whether Lilly can differentiate them versus existing therapies.

Sources

Key Facts

  • Eli Lilly (LLY) agreed to acquire Merida Biosciences for up to $2.875 billion.
  • The acquisition is intended to add antibody pipeline programs tied to Graves’ disease.
  • The added pipeline also targets thyroid eye disease.
  • The pipeline described in the report includes antibodies aimed at food allergy.
  • The report characterizes the deal mainly by disease targets rather than disclosing trial stage or program-by-program development plans.

Healthcare Related

Eli Lilly to buy Merida Biosciences in deal valued at up to $2.875 billion | The Apex Times